Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Ministry Revises Plan to Set First Generic Prices, Suggests 50% or 60%
November 28, 2013
- MHLW Proposes to “Institutionalize” New Drug Premium; Equivocal Wording Draws Fire at CSIMC
November 28, 2013
- RMPs Required for Generics when RMPs Submitted for Original Products: Health Ministry
November 27, 2013
- Nearly 60% of Face-to-Face Consultations from July 2011 through September 2013 Involved Drugs: PMDA
November 26, 2013
- Subcommittee Agrees to Introduction of New Price Reduction Rule for Long-Listed Drugs Next Year; Will Continue to Discuss Details
November 22, 2013
- JGA President Opposes 50% Rule for Generics, CSIMC Subcommittee Members Disagree
November 21, 2013
- Upper House Passes Amended Pharmaceutical Affairs Law and Law to Ensure Safety of Regenerative Medicine
November 21, 2013
- Decision on Long-Term Prescriptions to Be Based on Results of Discussions at CSIMC: Government
November 21, 2013
- Plan Floated to Merge NIBIO Unit, JST to Create Japan-Version NIH: Govt Source
November 20, 2013
- Finance Minister Pushes Drastic Price Cuts for Off-Patent Drugs with Low Generic Penetration
November 20, 2013
- Administrative Reform Council Calls for Further Promotion of Generics, Elimination of OTC-like Drugs from Insurance Coverage
November 20, 2013
- PAFSC’s Second Committee Supports Approval of NBI’s Lung Cancer Drug, Takeda’s Malignant Lymphoma Treatment
November 19, 2013
- PAFSC’s 1st Committee on Drugs to Review Astellas’s SGLT-2 Inhibitor Ipragliflozin on Nov. 29
November 19, 2013
- 1st Anticancer Drugs OK’ed for External Reviews under New Advanced Healthcare Scheme
November 18, 2013
- Subcommittee Agrees On Plan to Include Rate of Generic Drug Use in Determining Functional Evaluation Coefficient II for DPC Hospitals
November 18, 2013
- Reimbursement Listing of OBLEAN Put on Hold, Faces Rare CSIMC Setback
November 15, 2013
- MHLW Proposes Special Price Reductions for Long-Listed Drugs with Less than 60% of Generic Substitution After 5 Years
November 15, 2013
- Health Ministry Proposes to Set First Generic Prices at Half of Brand Name Drug Prices
November 14, 2013
- CSIMC OKs NHI Price Listing of 13 APIs, Takes Pass on Takeda’s OBLEAN
November 14, 2013
- Japan Govt OKs Bill to Allow Online Sales of OTC Drugs
November 14, 2013
ページ
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…